Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Dec 28;14(48):7361-70.
doi: 10.3748/wjg.14.7361.

Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis

Alexander C Ford  1 , Peter Malfertheiner, Monique Giguere, Jose Santana, Mostafizur Khan, Paul Moayyedi
Affiliations
Review

Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis

Alexander C Ford et al. World J Gastroenterol. .

Abstract

Aim: To assess the safety of bismuth used in Helicobacter pylori (H pylori) eradication therapy regimens.

Methods: We conducted a systematic review and meta-analysis. MEDLINE and EMBASE were searched (up to October 2007) to identify randomised controlled trials comparing bismuth with placebo or no treatment, or bismuth salts in combination with antibiotics as part of eradication therapy with the same dose and duration of antibiotics alone or, in combination, with acid suppression. Total numbers of adverse events were recorded. Data were pooled and expressed as relative risks with 95% confidence intervals (CI).

Results: We identified 35 randomised controlled trials containing 4763 patients. There were no serious adverse events occurring with bismuth therapy. There was no statistically significant difference detected in total adverse events with bismuth [relative risk (RR) = 1.01; 95% CI: 0.87-1.16], specific individual adverse events, with the exception of dark stools (RR = 5.06; 95% CI: 1.59-16.12), or adverse events leading to withdrawal of therapy (RR = 0.86; 95% CI: 0.54-1.37).

Conclusion: Bismuth for the treatment of H pylori is safe and well-tolerated. The only adverse event occurring significantly more commonly was dark stools.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of assessment of studies identified in the systematic review.
Figure 2
Figure 2
Forest plot of trials of bismuth or bismuth-containing regimens versus comparison regimen examining the effect on relative risk of any adverse event.
Figure 3
Figure 3
Forest plot of trials of bismuth or bismuth-containing regimens versus comparison regimen examining the effect on relative risk of dark stools.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tillman LA, Drake FM, Dixon JS, Wood JR. Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther. 1996;10:459–467. - PubMed
    1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;321:1273–1275. - PubMed
    1. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21:315–324. - PubMed
    1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315. - PubMed
    1. McNulty CA, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986;293:645–649. - PMC - PubMed

MeSH terms